Summary
The antimicrotubule agent taxol (NSC 125973) has shown clinical antitumor activity against several classically refractory tumors. We developed a drug-resistance profile for taxol using ten drug-resistant P388 leukemias to identify potentially useful guides for patient selection for further clinical trials of taxol and possible non-cross-resistant drug combinations with taxol. Multidrug-resistant P388 leukemias exhibited either clear (leukemia resistant to amsacrine) or marginal cross-resistance (leukemias resistant to doxorubicin, actinomycin D, and mitoxantrone) to taxol. Leukemias resistant to vincristine (non-multidrug-resistant leukemia), camptothecin, melphalan, cisplatin, 1-β-d-arabinofuranosylcytosine, and methotrexate were not cross-resistant to taxol. The data suggest that (1) it may be important to exclude or to monitor with extra care patients who have previously been treated with amsacrine, doxorubicin, actinomycin D, or mitoxantrone and (2) a combination of one of the non-cross-resistant drugs and taxol might exhibit therapeutic synergism.
This is a preview of subscription content, log in via an institution to check access.
References
Brewer F, Warr JR (1987) Verapamil reversal of vincristine resistance and cross-resistance patterns of vincristine-resistant Chinese hamster ovary cells. Cancer Treat Rep 71:353
Eng WK, McCabe FL, Tan KB, Mattern MR, Hofmann GA, Woessner RD, Hertzberg RP, Johnson RK (1990) Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content. Mol Pharmacol 38:471
Estey H, Hoth D, Simon R, Marsoni S, Leyland-Jones B, Wittes R (1986) Therapeutic response in phase I trials of antineoplastic agents. Cancer Treat Rep 70:1105
Johnson RK, Howard WS (1982) Development and cross-resistance characteristics of a subline of P388 leukemia resistant to 4′-(9-acridinylamino)methanesulfon-m-anisidide. Eur J Cancer Clin Oncol 18:479
Johnson RK, Chitnis MP, Embrey WM, Gregory EB (1978) In vivo characteristics of resistance and cross-resistance of an Adriamycin-resistant subline of P388 leukemia. Cancer Treat Rep 62:1535
Lloyd HH (1977) Application of tumor models toward the design of treatment schedules for cancer chemotherapy. In: Drewinko B, Humphrey RM (eds) Growth kinetics and biochemical regulation of normal and malignant cells. Williams & Wilkins, Baltimore, p 455
Rowinsky EK, Cazenave LA, Donehower RC (1990) Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 82:1247
Schabel FM Jr, Griswold DP Jr, Laster WR Jr, Corbett TH, Lloyd HH (1977) Quantitative evaluation of anticancer agent activity in experimental animals. Pharmacol Ther [A] 1:411
Teicher BA, Herman TS, Holden SA, Wang Y, Pfeffer MR, Crawford JW, Frei E III (1990) Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science 247:1457
Waud WR, Griswold DP Jr (1992) Therapeutic resistance in leukemia. In: Teicher BA (ed) Mechanisms of drug resistance in oncology. Marcel Dekker, New York (in press)
Waud WR, Harrison SD Jr, Gilbert KS, Laster WR Jr, Griswold DP Jr (1991) Antitumor drug cross-resistance in vivo in a cisplatin-resistant murine P388 leukemia. Cancer Chemother Pharmacol 27:456
Author information
Authors and Affiliations
Additional information
This work was supported by contract NO1-CM-07315 with the Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute
Rights and permissions
About this article
Cite this article
Waud, W.R., Gilbert, K.S., Harrison, S.D. et al. Cross-resistance of drug-resistant murine P388 leukemias to toxol in vivo. Cancer Chemother. Pharmacol. 31, 255–257 (1992). https://doi.org/10.1007/BF00685557
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00685557